

ASX ANNOUNCEMENT

Notice under section 708A of the Corporations Act 2001

28th April 2021, Brisbane, Australia

Analytica Limited (**Company**) has today issued 879,903,083 fully paid ordinary shares (**Shares**) in the Company at an issue price of 0.35 cents per Share.

In accordance with section 708A(6) of the *Corporations Act 2001* (Cth) (**Act**), the Company gives notice that:

- 1 The Shares were issued without disclosure to investors under Part 6D.2 of the Act.
- 2 This notice is being given under section 708A(5)(e) of the Act.
- 3 As at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
 - (b) section 674 of the Act.
- 4 As at the date of this notice, there is no excluded information as defined in section 708A(7) and section 708A(8) of the Act which is required to be disclosed by the Company.

This notice has been authorised for release to the ASX by the Board of the Company.

Dr Michael Monsour, Chairman

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.